$NTRA

Brophy Michael Burkes sold $1.3M of NTRA

Brophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 5,064 shares of Natera, Inc. (NTRA) at an average of $253.28 ($249.38–$260.49, $1.28M total) across 5 trades over 2026-07-27 to 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brophy Michael Burkes
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The only new information is the disclosed sale size, timing, and 10b5-1 status; it does not introduce new fundamentals.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a fundamental repricing by itself.

03

What to watch

The article does not provide context on total insider holdings, option exercises, or whether other insiders sold/bought around the same window.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29 for sales executed 2026-07-27 to 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CFO Brophy Michael Burkes sold about $1.28M of NTRA shares via an open-market sale under a 10b5-1 plan (Form 4).

Expected impact

Likely limited near-term impact; any effect is typically sentiment-only unless paired with other new fundamentals.

Evidence & confidence

The filing is a routine Form 4 open-market sale by the CFO, explicitly under a pre-arranged 10b5-1 plan, with no new guidance, deal, or regulatory action disclosed.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Because the trades were executed under a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose CFO filed the Form 4 insider sale disclosure.

  • Brophy Michael Burkes

    Natera CFO who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMedAI 8/10

Natera, Inc.: Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

$NTRAMed

Natera technology featured in 25 abstracts at ESMO congress

Natera Inc. (NTRA) presented cancer study results at the ESMO Congress 2026, with its technology featured in 25 abstracts. Key findings included high event-free survival rates in bladder cancer, high ctDNA detection in lung cancer, and predictive value in endometrial cancer. Studies also covered colorectal and gastroesophageal cancers.

$NTRALow

Natera, Inc. (NTRA) ctDNA Dynamics Predict EFS in MIBC

Natera (NTRA) reported phase III VOLGA trial data showing Signatera ctDNA dynamics predict event-free survival in MIBC, with 24-month EFS rates of 91% for persistently negative, 81% for cleared pre-surgery, and 55% for persistently positive. The company noted this as late-cycle validation for Signatera's role in MRD for bladder cancer.

$NTRAMed

Natera stock price target raised to $430 by BTIG on revenue outlook

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.